Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases

Jingjie Hu, Rebecca A. Bourne, Barbara C. McGrath, Alice Lin, Zifei Pei, Douglas R. Cavener

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

With the development of CRISPR-Cas9-mediated gene-editing technologies, correction of disease-causing mutations has become possible. However, current gene-correction strategies preclude mutation repair in post-mitotic cells of human tissues, and a unique repair strategy must be designed and tested for each and every mutation that may occur in a gene. We have developed a novel gene-correction strategy, co-opting regulation bypass repair (CRBR), which can repair a spectrum of mutations in mitotic or post-mitotic cells and tissues. CRBR utilizes the non-homologous end joining (NHEJ) pathway to insert a coding sequence (CDS) and transcription/translation terminators targeted upstream of any CDS mutation and downstream of the transcriptional promoter. CRBR results in simultaneous co-option of the endogenous regulatory region and bypass of the genetic defect. We validated the CRBR strategy for human gene therapy by rescuing a mouse model of Wolcott-Rallison syndrome (WRS) with permanent neonatal diabetes caused by either a large deletion or a nonsense mutation in the PERK (EIF2AK3) gene. Additionally, we integrated a CRBR GFP-terminator cassette downstream of the human insulin promoter in cadaver pancreatic islets of Langerhans, which resulted in insulin promoter regulated expression of GFP, demonstrating the potential utility of CRBR in human tissue gene repair.

Original languageEnglish (US)
Pages (from-to)3274-3292
Number of pages19
JournalMolecular Therapy
Volume29
Issue number11
DOIs
StatePublished - Nov 3 2021

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases'. Together they form a unique fingerprint.

Cite this